drugset / Trial / NCT01890343
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Non-randomizedParallel-groupSingle-blindDiagnostic
Summary
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease (AD).
Timeline
- Start
- 2009-09
- Primary completion
- 2012-12
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 185 mbq | Intravenous |
| Subject | florbetapir F 18 | Diagnostic / imaging agent | 300 mbq | Intravenous |